Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 13/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 8/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30583585 | 1.00 | GSK3B (0.47) | GSK3BGLACNR1S1PR1CNR2 | |
| SCHEMBL28747372 | 0.89 | CLK4 (0.46) | GSK3B | |
| SCHEMBL104898 | 0.83 | GLA (0.46) | GSK3BGLACNR1S1PR1CNR2 | |
| SCHEMBL3882898 | 0.83 | GSK3B (0.50) | GSK3BGLACNR1S1PR1CNR2 | |
| SCHEMBL11615116 | 0.83 | GSK3B (0.50) | GSK3BGLACNR1S1PR1CNR2 | |
| SCHEMBL27475654 | 0.82 | GSK3B (0.46) | GSK3BGLACNR1S1PR1CNR2 | |
| SCHEMBL23056923 | 0.80 | GLA (0.44) | GSK3BGLACNR1S1PR1CNR2 | |
| SCHEMBL6965820 | 0.80 | TRPA1 (0.57) | GSK3BCNR1CNR2ENPP2 | |
| SCHEMBL16959032 | 0.80 | GLA (0.44) | GSK3BGLACNR1S1PR1CNR2 | |
| SCHEMBL4095529 | 0.80 | ENPP2 (0.46) | GSK3BGLACNR1S1PR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | TAY THERAPEUTICS LTD (GB) | 2026-01-01 | — | — | US | disclosed |
| US-20250325687-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | MABSOFT THERAPEUTICS SHANGHAI CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2025-08-21 | — | — | US | disclosed |
| EP-3976617-B1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2025-04-23 | — | — | EP | disclosed |
| US-20240360082-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-112105610-B | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2024-01-26 | — | — | CN | disclosed |
| WO-2024018423-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| CN-1882529-A | Histone deacetylase inhibitors | METHYLGENE INC (CA) | 2006-12-20 | — | — | CN | disclosed |
| CN-1880317-A | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORP (US) | 2006-12-20 | — | — | CN | disclosed |
| CN-1753887-A | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals | SANNOFFE AVENTIS PHARMA GMBH (DE) | 2006-03-29 | — | — | CN | disclosed |
| CN-1735614-A | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORP (US) | 2006-02-15 | — | — | CN | disclosed |
| CN-1711243-A | 2-pyridone derivatives as inhibitors of neutrophil elastase | ASTRAZENECA AB (SE) | 2005-12-21 | — | — | CN | disclosed |
| CN-1520416-A | Carbohydrate derivatives | Ĭ��ר���ɷ�����˾ | 2004-08-11 | — | — | CN | disclosed |
| EP-1276726-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | Abbott Laboratories (US) | 2003-01-22 | — | — | EP | disclosed |
| CN-1361765-A | Aspartyl protease inhibitors | VERTEX PHARMA (US) | 2002-07-31 | — | — | CN | disclosed |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
| WO-2001081316-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, BRD4, PHKB | GSK3B 2851/4885GLA 2830/4885CNR1 131/4885 |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, PHKB, BRD4 | GSK3B 2014/4885GLA 3687/4885CNR1 3394/4885 |
| US-20250325687-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | TLR3, TLR7, TLR8 | GSK3B 2844/4885GLA 3845/4885CNR1 378/4885 |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | FNTA, FNTB, SLC10A1 | GSK3B 1456/4885GLA 1111/4885CNR1 2465/4885 |
| US-20240360082-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | PNPO, PDXK, PLPBP | GSK3B 1355/4885GLA 2823/4885CNR1 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.